Colorectal cancer is a significant burden of disease in the developed world.[@CR1] Surgical resection continues to form the cornerstone of management of this disease. However, surgery is not without problems in terms of postoperative morbidity and mortality.[@CR2] Furthermore, it has become clear that postoperative complications following surgery for colorectal cancer are not only associated with poor short-term outcomes but also with poorer long-term outcomes.[@CR3]--[@CR6]

Postoperative complications have previously been defined as "deviation from the normal postoperative course."[@CR7] They have been classified by type, primarily as infective or noninfective, or by severity using the Clavien-Dindo scale.[@CR3],[@CR7]--[@CR10] There is good evidence that the type of complication, in particular infective complications, has a significant negative impact on cancer-specific and overall survival following surgery for colorectal cancer.[@CR11],[@CR12] Fewer studies have examined the impact of complication severity on long-term outcomes, although those that have reported poorer disease-free and overall survival.[@CR13],[@CR14] Indeed, a recent meta-analysis reported that severe complications had a greater impact on long-term outcomes following surgery for colorectal cancer.[@CR15]

The magnitude of the systemic inflammatory response, as evidenced by postoperative CRP thresholds of 190 mg/L on postoperative day (POD) 2, 170 mg/L on POD 3, and 145 mg/L on POD 4, have been reported to be associated with the development of infective complications.[@CR16]--[@CR18] More recently, a comprehensive review suggested that CRP concentrations above a threshold of 150 mg/L on POD 3--5 should prompt investigation and or treatment of potential postoperative complications in colorectal surgery.[@CR19] Two recent studies have examined the relationship between the magnitude of the postoperative systemic inflammatory response, as measured by CRP, and the severity of complications following surgery for colorectal cancer.[@CR20],[@CR21] Moreover, two recent studies in oesophagogastric cancer have suggested that CRP concentrations in the postoperative period are significantly associated with survival independent of postoperative complications.[@CR22],[@CR23] To the authors knowledge, no study investigating the interaction between the magnitude of the postoperative systemic inflammatory response and complication severity, and their impact on long-term outcomes has been performed in colorectal cancer surgery.

Therefore, the purpose of the present study was to examine the relationship between the magnitude of the postoperative systemic inflammatory response and complication severity and to determine which, if any, had the greatest impact on long-term outcomes following surgery for colorectal cancer.

Patients and Methods {#Sec1}
====================

Patients {#Sec2}
--------

This observational study included patients who underwent elective, potentially curative surgery for histologically confirmed colorectal cancer in a single centre between March 2008 and May 2013. Patients with metastatic disease who underwent palliative procedures or had existing inflammatory conditions were excluded.

All patients received prophylactic antibiotics and venous thromboprophylaxis prior to the induction of anaesthesia as per hospital policy. All patients were cared for in line with a unit standardised enhanced recovery after surgery (ERAS) protocol, which included preoperative carbohydrate drinks, early mobilisation, and early enteral nutrition, with the avoidance of routine peritoneal and/or nasogastric drainage. On each POD, patients were clinically assessed and had blood samples, including serum CRP, obtained as standard until discharged. Further postoperative investigation and intervention was at the discretion of the patient's surgical team who were not blind to postoperative blood results.

Methods {#Sec3}
=======

All data were collected prospectively in a database, anonymised, and subsequently analysed. Recorded information included patient demographics, tumour site, TNM stage (TNM, AJCC), surgical approach, whether adjuvant or neoadjuvant treatment was given, whether the presentation was elective or emergency, the presence of complications, preoperative serum CRP, and albumin measurements. Data regarding the nature, severity, and management of complications was retrospectively categorised using the Clavien-Dindo scale.[@CR7] Any uncertainties were addressed by review of electronic and/or physical case notes. Date and cause of death were crosschecked with the Registrar General (Scotland). Death records were complete until June 30, 2015, which served as the censor date. The study was approved by the West of Scotland Research Ethics Committee, Glasgow.

Serum concentrations of CRP (mg/L) were measured using an autoanalyzer (Architect; Abbot Diagnostics, Maidenhead, UK) with a lower detectable limit of 0.2 mg/L as was serum albumin (normal range 35--50 g/L). The preoperative modified Glasgow Prognostic Score (mGPS) was calculated from preoperative serum CRP and albumin.[@CR24]

Statistical Analysis {#Sec4}
--------------------

Categorical data regarding patient characteristics were compared using the Chi square test and Chi square test for linear association where appropriate. Patients who underwent colonic resection were analysed as a subgroup due to significant differences in postoperative complication rates between those with colonic and rectal cancers. Those patients who died within 30 days of surgery or during the same admission (Clavien-Dindo grade 5 complications) were excluded from survival analysis. Univariate and multivariate survival data were analysed using Cox's proportional hazards model. Variables associated with disease-specific or overall survival at a significance level of *p* \< 0.1 on univariate analysis were included in multivariate modelling using backward conditional regression where a two-sided *p* value \<0.05 was considered statistically significant. Disease-specific survival was defined as time from date of surgery to date of cancer-specific death. Overall survival was defined as time from date of surgery to date of death from any cause. Statistical analyses were performed using IBM SPSS version 22 for Windows (Chicago, IL).

Results {#Sec5}
=======

Patients {#Sec6}
--------

A total of 377 patients were included having undergone potentially curative surgery for colorectal cancer in the absence of metastatic disease. The majority were male (55 %), older than age 65 years (68 %), with colonic (63 %) and node-negative disease (66 %). In total, 110 patients (29 %) had a laparoscopic resection, and the remainder had open surgery. Amongst the 138 patients with rectal cancer, 65 (47 %) with locally advanced or margin-threatening disease had neoadjuvant treatment, of which 10 (15 %) were subsequently found to have had a pathological complete response. Of all included patients, 29 % had adjuvant treatment following surgery.

Complications {#Sec7}
-------------

Of 377 patients, 138 (37 %) experienced complications (Table [1](#Tab1){ref-type="table"}). Four patients (1 %) died within 30 days of surgery or during the same admission. When classified using the Clavien-Dindo scale, 108 (30 % of all patients) were grade 1--2 (i.e., required minor intervention) and 26 (6 %) were grade 3--4 (i.e., necessitated major intervention). When patient's demographic, pathological, and clinical characteristics were compared across complication severity (Table [2](#Tab2){ref-type="table"}), male gender (*p* \< 0.01), ASA grade (*p* \< 0.05), smoking status (*p* \< 0.05), and rectal cancer (*p* \< 0.05) were significantly associated with Clavien-Dindo grade. There was a significant association between complication severity and the proportion of patients breaching the established CRP threshold of 150 mg/L on POD 2 (*p* = 0.004), POD 3, and POD 4 (both *p* \< 0.001).Table 1Postoperative complications by severityComplication*n*%No complication23963Any complication13837Complication type Infective  All infective complications9425   SSI    Wound infection4311.5    Anastomotic leak164    Intra-abdominal abscess62   RSI    Pneumonia236    Septicaemia20.5    UTI41 Noninfective  All noninfective complications4412   Wound    Seroma20.5    Dehiscence41   Surgical site    Haemorrhage10.25   Cardiac    MI41    Arrhythmia92.5   Vascular    VTE30.75    CVA20.5   Urinary    Renal failure41    Acute urinary retention30.75   Gastrointestinal    Diarrhoea (noninfective)41    Ileus82.25Complication severity Clavien-Dindo Grade  023963  13610  27220  3184  482  541*SSI* surgical site infection, *RSI* remote site infection, *UTI* urinary tract infection, *MI* myocardial infarction, *VTE* venous thromboembolism, *CVA* cerebrovascular accidentTable 2Patient characteristics by severity of complication following surgery for colorectal cancerCharacteristicAllClavien-Dindo complication grade0^a^1--2^b^3--4^c^5^d^*pN* (%)377 (100)239 (63)108 (30)26 (7)4 (1)--Age (\<65/65--74/\>74)122/149/10682/96/6131/44/339/7/100/2/20.451Sex (male/female)208/169116/12374/3415/113/10.005BMI (\<20/20--25/36--30/\>30)16/112/114/9012/69/75/553/32/31/28/941/8/8/60/3/0/10.833ASA (1/2/3/4)48/169/145/1436/112/83/79/45/48/63/11/12/00/1/2/10.014Smoking (never/ex/current)159/150/61114/89/3137/46/238/11/70/4/00.015Preop mGPS (0/1/2)284/37/56180/23/3682/9/1718/5/34/0/00.636Site (colon/rectum)239/138160/7963/4516/100/40.024TNM stage (0/I/II/III)10/80/159/1288/54/101/761/20/43/440/5/14/71/1/1/10.120Neoadjuvant treatment (no/yes)299/65191/4084/1921/53/10.970Approach (open/laparoscopic)266/110162/7783/2418/83/10.323Surgery \> 4 h (yes/no)83/24751/15422/769/161/10.456Stoma (yes/no)115/26265/17439/698/181/10.087POD 2 CRP \> 150 mg/L (yes/no)205/162114/11772/3516/93/10.004POD 3 CRP \> 150 mg/L (yes/no)187/169100/12467/3819/51/2\<0.001POD 4 CRP \> 150 mg/L (yes/no)126/20058/13751/5116/101/2\<0.001Adjuvant treatment (no/yes)269/108171/6873/3521/54/00.323*mGPS* preoperative modified Glasgow Prognostic score (0 = CRP \< 10 mg/L, 1 = CRP ≥ 10 mg/L and albumin ≥ 35 g/L, 2 = CRP ≥ 10 mg/L and albumin \< 35 g/L)*POD* postoperative day^a^0 = no complication^b^1--2 = complication requiring minor intervention^c^3--4 = complication requiring significant intervention^d^5 = death

Follow-Up {#Sec8}
---------

After exclusion of postoperative mortality (4, 1 %), death due to any cause occurred in 81 patients (22 %); 53 (14 %) were cancer-specific. The median follow-up for patients alive at the time of their censoring was 46 (range 24--86) months.

Disease-Specific Survival {#Sec9}
-------------------------

On univariate analysis (Table [3](#Tab3){ref-type="table"}), age \[hazard ratio (HR) 1.54, 95 % confidence interval (CI) 1.08--2.21, *p* = 0.018\], ASA grade (HR 1.69, 95 % CI 1.16--2.46, *p* = 0.007), TNM stage (HR 2.50, 95 % CI 1.63--3.85, *p* \< 0.001), mGPS (HR 1.67, 95 % CI 1.23--2.26, *p* = 0.001), breaching the established CRP threshold of 150 mg/L on POD 3 (HR 1.84, 95 % CI 1.01--3.35, *p* = 0.047) and POD 4 (HR 2.53, 95 % CI 1.43--4.48, *p* = 0.001) and complication severity (HR 1.66, 95 % CI 1.13--2.43, *p* = 0.009) were associated with disease-specific survival and included in multivariate analysis. On multivariate analysis (Table [3](#Tab3){ref-type="table"}), ASA grade (HR 1.52, 95 % CI 1.01--2.28, *p* = 0.044), mGPS (HR 1.49, 95 % CI 1.08--2.07, *p* = 0.016), TNM stage (HR 2.46, 95 % CI 1.52--3.96, *p* \< 0.001), and breaching the established CRP threshold of 150 mg/L on POD 4 (HR 2.00, 95 % CI 1.12--3.59, *p* = 0.020) remained independently associated with poorer disease-specific survival. Breaching the established CRP threshold of 150 mg/L on POD 3 was not included in multivariate analysis, because it was directly associated with breaching the established CRP thresholds of 150 mg/L on POD 4, which had a greater statistical significance on univariate analysis.Table 3Impact of the severity of postoperative complications on survival following surgery for colorectal cancer, univariate and multivariate survival analysisSurvivalVariableUnivariate HR (95 % CI)*p*Multivariate HR (95 % CI)*p*DSSAge1.54 (1.08--2.21)0.018--0.225Sex0.77 (0.45--1.32)0.344----BMI0.88 (0.62--1.23)0.446----ASA1.69 (1.16--2.46)0.0071.52 (1.01--2.28)0.044Smoking1.00 (0.69--1.46)0.984----mGPS1.67 (1.23--2.26)0.0011.49 (1.08--2.07)0.016Rectal1.00 (0.57--1.74)0.998----TNM stage2.50 (1.63--3.85)\<0.0012.46 (1.52--3.96)\<0.001Neoadjuvant treatment1.23 (0.63--2.39)0.548----POD 2 CRP \> 150 mg/L1.62 (0.91--2.89)0.101----POD 3 CRP \> 150 mg/L1.84 (1.01--3.35)0.047----POD 4 CRP \> 150 mg/L2.53 (1.43--4.48)0.0012.00 (1.17--3.59)0.020Clavien-Dindo grade1.66 (1.13--2.43)0.0091.51 (0.98--2.33)0.061Adjuvant treatment0.78 (0.42--1.46)0.432----OSAge1.83 (1.36--2.48)\<0.0011.35 (0.97--1.87)0.074Sex1.06 (0.68--1.64)0.799----BMI0.85 (0.65--1.12)0.242----ASA1.92 (1.41--2.61)\<0.0011.49 (1.05--2.10)0.024Smoking1.20 (0.89--1.61)0.238----mGPS1.52 (1.18--1.96)0.001--0.170Rectal0.78 (0.49--1.25)0.308----TNM stage1.70 (1.25--2.31)0.0012.12 (1.45--3.41)\<0.001Neoadjuvant treatment0.97 (0.54--1.73)0.914----POD 2 CRP \> 150 mg/L1.99 (1.22--3.26)0.006----POD 3 CRP \> 150 mg/L1.76 (1.08--2.85)0.022----POD 4 CRP \> 150 mg/L2.02 (1.27--3.20)0.0032.14 (1.34--3.41)0.001Clavien-Dindo grade1.30 (0.93--1.81)0.127----Adjuvant treatment0.64 (0.37--1.09)0.0980.33 (0.17--0.64)0.001*HR* hazard ratio, *CI* confidence interval, *DSS* disease-specific survival, *OS* overall survival, *mGPS* modified Glasgow Prognostic score, *POD* postoperative day

Overall Survival {#Sec10}
----------------

On univariate analysis (Table [3](#Tab3){ref-type="table"}), age (HR 1.83, 95 % CI 1.36--2.48, *p* \< 0.001), ASA grade (HR 1.92, 95 % CI 1.41--2.61, *p* \< 0.001), mGPS (HR 1.52, 95 % CI 1.18--1.96, *p* = 0.001), TNM stage (HR 1.70, 95 % CI 1.25--2.31, *p* = 0.001), breaching the established CRP threshold of 150 mg/L on POD 2 (HR 1.99, 95 % CI 1.22--3.26, *p* = 0.006, POD 3 (HR 1.76, 95 % CI 1.08--2.85, *p* = 0.022), and POD 4 (HR 2.02, 95 % CI 1.27--3.20, *p* = 0.003), and adjuvant treatment (HR 0.64, 95 % CI 0.37--1.09, *p* = 0.098) were associated with overall survival and included in multivariate analysis. On multivariate analysis (Table [3](#Tab3){ref-type="table"}), ASA grade (HR 1.49, 95 % CI 1.05--2.10, *p* = 0.024), TNM stage (HR 2.12, 95 % CI 1.45--3.09, *p* \< 0.001), breaching the established CRP threshold of 150 mg/L on POD 4 (HR 2.14, 95 % CI 1.34--3.41, *p* = 0.001), and adjuvant treatment (HR 0.33, 95 % CI 0.17--0.64, *p* = 0.001) all remained independently associated with overall survival. Breaching the established CRP threshold of 150 mg/L on POD 2 and 3 were not included in multivariate analysis, because they were directly associated with breaching the established CRP thresholds of 150 mg/L on POD 4, which had a greater statistical significance on univariate analysis.

Colonic Resection {#Sec11}
-----------------

When the subgroup of 239 patients who underwent surgery for colonic cancer were considered, 79 (33 %) experienced complications (Table [4](#Tab4){ref-type="table"}). No patients died within 30 days of surgery or during the same admission. When classified using the Clavien-Dindo scale, 63 were grade 1--2 and 16 were grade 3--4. When patient's demographic, pathological, and clinical characteristics were compared across complication severity (Table [3](#Tab3){ref-type="table"}), only smoking status (*p* = 0.047) was significantly associated. There was a significant association between complication severity and the proportion of patients breaching the established CRP threshold of 150 mg/L on POD 2 (*p* = 0.032), POD 3 (*p* = 0.002), and POD 4 (*p* = 0.005).Table 4Patient characteristics by severity of complication following surgery for colonic cancerCharacteristicAllClavien-Dindo complication grade0^a^1--2^b^3--4^c^5^d^*pN* (%)23916063160--Age (\<65/65--74/\>74)66/88/8548/59/5314/24/254/5/70/0/00.724Sex (male/female)127/11277/8342/218/80/0/00.111BMI (\<20/20--25/36--30/\>30)11/64/68/609/41/50/381/19/12/191/4/6/30/0/0/00.430ASA (1/2/3/4)24/99/105/1120/70/63/72/23/34/42/6/8/00/0/0/00.227Smoking (never/ex/current)103/91/4079/54/2320/30/124/7/50/0/00.047Preop mGPS (0/1/2)170/28/41115/18/2746/6/119/4/30/0/00.513TNM stage (0/I/II/III)0/50/112/770/33/73/540/14/29/200/3/10/30/0/0/00.734Approach (open/laparoscopic)83/15657/10320/436/100/00.836Surgery \> 4 h (yes/no)28/17917/1187/504/110/00.303Stoma (yes/no)14/1587/1136/371/80/00.277POD 2 CRP \> 150 mg/L (yes/no)129/10578/7843/198/80/00.032POD 3 CRP \> 150 mg/L (yes/no)121/10569/8141/2011/40/00.002POD 4 CRP \> 150 mg/L (yes/no)81/11741/8431/269/70/00.005Adjuvant treatment (no/yes)69/17048/11218/453/130/00.638*mGPS* preoperative modified Glasgow Prognostic score (0 = CRP \< 10 mg/L, 1 = CRP ≥ 10 mg/L and albumin ≥ 35 g/L, 2 = CRP ≥ 10 mg/L and albumin \< 35 g/L)*POD* postoperative day^a^0 = no complication^b^1--2 = complication requiring minor intervention^c^3--4 = complication requiring significant intervention^d^5 = death

On multivariate analysis (Table [5](#Tab5){ref-type="table"}) mGPS (HR 1.81, 95 % CI 1.20--2.72, *p* = 0.005), TNM stage (HR 2.28, 95 % CI 1.23--4.21, *p* = 0.009), and breaching the established CRP threshold of 150 mg/L on POD 4 (HR 2.42, 95 % CI 1.13--5.18, *p* = 0.023) were independently associated with disease specific survival after surgery for colonic cancer. ASA grade (HR 1.99, 95 % CI 1.28--3.10, *p* = 0.002), mGPS (HR 1.53, 95 % CI 1.11--2.10, *p* = 0.010), and breaching the established CRP threshold of 150 mg/L on POD 4 (HR 2.32, 95 % CI 1.29--4.20, *p* = 0.005) were independently associated with overall survival after surgery for colonic cancer.Table 5Impact of the severity of postoperative complications on survival following surgery for colonic cancer, univariate and multivariate survival analysisSurvivalVariableUnivariate HR (95 % CI)*p*Multivariate HR (95 % CI)*p*DSSAge1.52 (0.96--2.41)0.073--0.316Sex0.72 (0.37--1.44)0.356----BMI0.69 (0.44--1.09)0.109----ASA1.63 (1.00--2.67)0.0511.70 (0.99--2.93)0.057Smoking0.94 (0.58--1.52)0.792----mGPS1.95 (1.34--2.82)\<0.0011.81 (1.20--2.72)0.005TNM stage2.27 (1.32--3.90)0.0032.28 (1.23--4.21)0.009POD 2 CRP \> 150 mg/L1.69 (0.82--3.48)0.157----POD 3 CRP \> 150 mg/L1.97 (0.89--4.36)0.094----POD 4 CRP \> 150 mg/L2.78 (1.31--5.91)0.0082.42 (1.13--5.18)0.023Clavien-Dindo grade1.34 (1.01--1.78)0.043--0.164Adjuvant treatment0.77 (0.35--1.70)0.516----OSAge1.78 (1.23--2.57)0.0021.43 (0.94--2.15)0.092Sex1.04 (0.61--1.78)0.873----BMI0.75 (0.53--1.06)0.100----ASA1.98 (1.34--2.93)0.0011.99 (1.28--3.10)0.002Smoking1.19 (0.83--1.70)0.354----TNM stage1.53 (1.04--2.25)0.030--0.114mGPS1.66 (1.23--2.23)0.0011.53 (1.11--2.10)0.010POD 2 CRP \> 150 mg/L2.18 (1.20--3.96)0.010----POD 3 CRP \> 150 mg/L1.88 (1.03--3.42)0.040----POD 4 CRP \> 150 mg/L2.33 (1.31--4.17)0.0042.32 (1.29--4.20)0.005Clavien-Dindo grade1.08 (0.84--1.39)0.548----Adjuvant treatment0.67 (0.35--1.27)0.205----*HR* hazard ratio, *CI* confidence interval, *DSS* disease-specific survival, *OS* overall survival, *mGPS* modified Glasgow Prognostic score, *POD* postoperative day

Discussion {#Sec12}
==========

The results of the present study report a significant association between the magnitude of the postoperative systemic inflammatory response and complication severity, using the Clavien-Dindo grade, following surgery for colorectal cancer. Furthermore, the magnitude of the postoperative systemic inflammatory response, in particular CRP on POD 4, was significantly associated with disease-specific and overall survival independent of postoperative complications. These relationships remained in a subgroup of patients who underwent colonic surgery. Therefore, the present results would suggest that the relationship between postoperative complication severity and poorer long-term survival is, at least in part, dependent on the magnitude of the postoperative systemic inflammatory response.

The results of the present study are consistent with previous studies showing an association between male gender, preoperative ASA grade, smoking status, and complication severity following colorectal surgery.[@CR19],[@CR25],[@CR26] Moreover, with two recent studies reporting the association between complication severity and the magnitude of the postoperative systemic inflammatory response in patients with colorectal cancer and also in patients undergoing surgery for gastric and oesophageal cancer.[@CR20]--[@CR23]

A recent meta-analysis reported that complication type and severity were independently associated with poorer oncologic outcomes following colorectal surgery and liver resection for colorectal cancer.[@CR15] However, the present study is the first to include a measure of the magnitude of the systemic inflammatory response together with the severity of complication in survival analysis following surgery for colorectal cancer. Although the relationship between postoperative infective complications and poorer survival in patients with colorectal cancer has been extensively documented, complication severity using the Clavien-Dindo scale provides a validated, objective framework for the definition of such postoperative complications.[@CR10]

Taken together the implications of these results are important. They would suggest that the mechanisms that link the magnitude of the postoperative systemic inflammatory response, postoperative complications, and poorer oncological outcomes are inflammatory in aetiology.[@CR27] In previous work, it has been reported that the presence of preoperative systemic inflammation, as measured by the mGPS, but not postoperative complication, was associated with poorer long-term outcomes following surgery for colorectal cancer.[@CR8] However, the magnitude of the postoperative systemic inflammatory response was not considered. More recently, it is now recognised that the magnitude of the systemic inflammatory response following surgery for colorectal cancer is associated with the extent of postoperative complications.[@CR17],[@CR18],[@CR20],[@CR21] The present study shows that both the pre- and postoperative systemic inflammatory responses are associated with oncologic outcomes independent of tumour stage and postoperative complications.

The exact mechanisms underlying these relationships are unclear. However, the presence of an innate immune driven systemic inflammatory response can suppress cytotoxic immunity and may promote the development of postoperative complications and tumour progression.[@CR28]--[@CR30] If this were proven to be the case, it therefore would be rational to consider the postoperative systemic inflammatory response a target for therapeutic intervention. Clearly, such therapeutic intervention also would test the above hypothesis, because it would be anticipated that a reduction in the postoperative systemic inflammatory response would not only result in a reduction in the severity of postoperative complications but also improve long-term outcomes, not only in colorectal cancer surgery, but in surgery for all solid tumours. It remains to be determined whether the modulation of the postoperative systemic inflammatory response may reduce the frequency and/or severity of postoperative complications or improve long-term outcomes following surgery for colorectal cancer.

Therefore, it is of interest that several meta-analyses investigating trials of preoperative corticosteroids in major abdominal and gastrointestinal surgery have suggested a reduction in both the magnitude of the postoperative systemic inflammatory response and postoperative complications.[@CR31]--[@CR33] The long-term outcomes of these trials however is less clear; two, small follow-up studies suggested that preoperative corticosteroids had a potentially negative oncologic impact.[@CR34],[@CR35] However, preoperative corticosteroids have been widely incorporated into perioperative care guidelines for colorectal surgery due to their efficacy in the reduction of rates of postoperative nausea and vomiting.[@CR36] Other strategies might include the use of NSAIDs, H~2~ receptor antagonists, or statins in the perioperative period, each of which have been suggested to attenuate the systemic inflammatory response in patients with cancer.[@CR29],[@CR37] Additionally, laparoscopic surgery has been associated with a reduction in the magnitude of the postoperative systemic inflammatory response where technically appropriate.[@CR38]

A main limitation of the present study was the relatively short follow-up period. In addition, a relatively small number of Clavien-Dindo grade 3--4 complications occurred. The significant difference in frequency of severe complication between colonic and rectal resection led to the separate analysis of patients undergoing colonic resection. Nevertheless, comparative analysis showed similar significant relationships with survival compared with the whole cohort.

In summary, the results of the present study show that the magnitude of the postoperative systemic inflammatory response was associated with oncologic outcome following surgery for colorectal cancer, independent of postoperative complications, or disease stage.
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